Dupilumab

Showing 4 posts of 4 posts found.

sanofi_new_paris_hq

Patients in UK to be given early access to Sanofi’s eczema treatment

March 14, 2017
Research and Development, Sales and Marketing Dupilumab, MHRA, Sanofi

Sanofi’s treatment for atopic dermatitis, otherwise known as eczema, has been given a positive scientific opinion through the MHRA’s Early …

sample

Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials

June 6, 2016
Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials

Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …

Sanofi and Regeneron announce positive Phase III trial results for chronic skin disease treatment

April 1, 2016
Medical Communications, Research and Development Dupilumab, Regeneron, Sanofi, atopic dermatitis, phase III, skin disease

Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have announced positive top line results for dupilumab in Phase III clinical …

Positive news for Sanofi asthma drug

May 23, 2013
Sales and Marketing Dupilumab, Regeneron, Sanofi, asthma

An asthma drug being developed by Sanofi and Regeneron Pharmaceuticals has performed well in a Phase IIa trial, reducing the …

Latest content